Craft

Myriad Genetics

Stock Price

$16.6

2023-09-22

Market Capitalization

$1.4 B

2023-09-22

Revenue

$678.4 M

FY, 2022

Myriad Genetics Summary

Company Summary

Overview
Myriad Genetics is a genetic testing and precision medicine company. It specializes its products, capabilities, and expertise in three areas: oncology, women's health, and mental health. The company develops molecular diagnostic tests designed to analyze genes and their expression levels to assess an individual’s risk for developing disease, determine a patient’s likelihood of responding to a particular drug, or assess a patient’s risk of disease progression.
Type
Public
Status
Active
Founded
1991
HQ
Salt Lake City, UT, US | view all locations
Website
https://www.myriad.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Paul J. Diaz

    Paul J. Diaz, President, CEO & Director

  • Bryan Riggsbee

    Bryan Riggsbee, Chief Financial Officer & EVP

  • Kevin R. Haas

    Kevin R. Haas, Chief Technology Officer

  • Jayne B. Hart

    Jayne B. Hart, Chief People Officer

Operating MetricsView all

Facilities Leased, sq. ft.

500.1K
33.6%

FY, 2022

Products

10

FY, 2021

Website Visitors

135K

FY, 2021

LocationsView all

8 locations detected

  • Salt Lake City, UT HQ

    United States

    320 Wakara Way

  • Mason, OH

    United States

    6960 Cintas Blvd

  • South San Francisco, CA

    United States

    180 Kimball Way

  • Issy-les-Moulineaux, IDF

    France

    41 Rue Camille Desmoulins

  • München, BY

    Germany

    Staffelseestraße 6

  • Schiphol, Noord-Holland

    Netherlands

    231 Schiphol Boulevard

and 2 others

Myriad Genetics Financials

Summary Financials

Revenue (Q2, 2023)
$183.5M
Gross profit (Q2, 2023)
$125.7M
Net income (Q2, 2023)
($116.1M)
Cash (Q2, 2023)
$102.8M
EBIT (Q2, 2023)
($113.7M)
Enterprise value
$1.3B

Footer menu